Last reviewed · How we verify
Sanjin tablets simulants
Sanjin tablets is a traditional Chinese medicine formulation that promotes blood circulation and removes blood stasis to treat inflammatory and thrombotic conditions.
Sanjin tablets is a traditional Chinese medicine formulation that promotes blood circulation and removes blood stasis to treat inflammatory and thrombotic conditions. Used for Blood stasis-related conditions, Thrombotic disorders, Inflammatory conditions.
At a glance
| Generic name | Sanjin tablets simulants |
|---|---|
| Also known as | Levofloxacin |
| Sponsor | China Academy of Chinese Medical Sciences |
| Drug class | Traditional Chinese medicine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Hematology |
| Phase | FDA-approved |
Mechanism of action
Sanjin tablets contains herbal ingredients traditionally used in Chinese medicine to improve microcirculation, reduce inflammation, and prevent blood clotting. The formulation is believed to work through multiple pathways affecting coagulation, fibrinolysis, and inflammatory mediators, though the exact molecular mechanisms have not been fully characterized in Western pharmacological terms.
Approved indications
- Blood stasis-related conditions
- Thrombotic disorders
- Inflammatory conditions
Common side effects
- Gastrointestinal upset
- Bleeding risk
Key clinical trials
- Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sanjin tablets simulants CI brief — competitive landscape report
- Sanjin tablets simulants updates RSS · CI watch RSS
- China Academy of Chinese Medical Sciences portfolio CI